Login to Your Account

Spectrum's Pivotal BELIEF: PTCL Data 'Topo' the Mark

By Randy Osborne
Staff Writer

Friday, December 21, 2012
Spectrum Pharmaceuticals Inc.'s endpoint-beating success in the pivotal Phase II study with belinostat for relapsed/refractory peripheral T-cell lymphoma keeps the firm on track potentially to pair the pan-histone deacetylase inhibitor with Spectrum's antifolate Folotyn, already approved for the condition.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription